- Active not recruitingPHASE3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
This study is for children and young people under 25 with a type of brain tumour called low-grade glioma. It compares a new medicine, tovorafenib, with standard chemotherapy to see which works best and is safest for those needing first-time treatment.
For: Low-grade Glioma · Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma · Pediatric Low-grade GliomaUnited States · Australia · Austria - RecruitingPHASE2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This study is looking into a new medicine, Tovorafenib, for children and young adults aged 6 months to 25 years in the UK. It focuses on those with specific types of brain tumours (low-grade glioma) or advanced solid tumours that have come back or gotten worse, especially if they have certain genetic changes.
For: Low-grade Glioma · Advanced Solid TumorUnited States · Australia · Canada - AuthorisedPhase I and Phase II (Integrated)- Other
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
This study is looking into new combination treatments for children and young people with a type of brain tumour called low-grade glioma that has come back or is getting worse. It's testing if combining existing medicines is safe and helps shrink the tumour.
For: progressive/relapsed/refractory pediatric low-grade glioma (pLGG)Denmark · Czechia · Austria